CN105122068A - 蛋白质组学ipf标志物 - Google Patents

蛋白质组学ipf标志物 Download PDF

Info

Publication number
CN105122068A
CN105122068A CN201480021359.5A CN201480021359A CN105122068A CN 105122068 A CN105122068 A CN 105122068A CN 201480021359 A CN201480021359 A CN 201480021359A CN 105122068 A CN105122068 A CN 105122068A
Authority
CN
China
Prior art keywords
lung disease
fibrotic lung
pulmonary disease
marker protein
disease marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480021359.5A
Other languages
English (en)
Chinese (zh)
Inventor
K·科森
X·秦
S·R·利姆
S·D·赛韦特
D·鲁尔蒙德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of CN105122068A publication Critical patent/CN105122068A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
CN201480021359.5A 2013-03-15 2014-03-14 蛋白质组学ipf标志物 Pending CN105122068A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361801476P 2013-03-15 2013-03-15
US201361801290P 2013-03-15 2013-03-15
US61/801,476 2013-03-15
US61/801,290 2013-03-15
US201361874947P 2013-09-06 2013-09-06
US61/874,947 2013-09-06
PCT/US2014/029392 WO2014144821A1 (en) 2013-03-15 2014-03-14 Proteomic ipf markers

Publications (1)

Publication Number Publication Date
CN105122068A true CN105122068A (zh) 2015-12-02

Family

ID=51537804

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480021359.5A Pending CN105122068A (zh) 2013-03-15 2014-03-14 蛋白质组学ipf标志物

Country Status (11)

Country Link
US (1) US9726677B2 (https=)
EP (1) EP2972392A4 (https=)
JP (1) JP2016519763A (https=)
KR (1) KR20150130408A (https=)
CN (1) CN105122068A (https=)
BR (1) BR112015023699A2 (https=)
CA (1) CA2901384A1 (https=)
HK (1) HK1219533A1 (https=)
MX (1) MX2015012778A (https=)
RU (1) RU2015144149A (https=)
WO (1) WO2014144821A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107677835A (zh) * 2017-09-26 2018-02-09 上海市肺科医院 一种ae‑ipf的蛋白标记物及其应用
CN113533750A (zh) * 2020-10-22 2021-10-22 广州中医药大学顺德医院(佛山市顺德区中医院) 一种区分新型冠状病毒肺炎患者与健康者的系统
CN113607955A (zh) * 2020-09-16 2021-11-05 广州中医药大学顺德医院(佛山市顺德区中医院) 新型冠状病毒肺炎分期与疗效评估细胞因子标志物及其应用
CN117025745A (zh) * 2022-11-18 2023-11-10 中国医学科学院北京协和医院 分子标志物在诊断干燥综合征中的应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
RU2015144149A (ru) 2013-03-15 2017-04-21 Интермьюн, Инк. Протеомные маркеры илф
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP3215170A4 (en) 2014-11-05 2018-04-25 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
WO2018191751A1 (en) * 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizonia Compositions and methods for treating pulmonary fibrosis
US10975167B2 (en) 2017-04-14 2021-04-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Method to reduce pulmonary arterial hypertension by administering inhibitors of nicotinamide phosphoribotransferase
CN113260863A (zh) * 2018-08-17 2021-08-13 豪夫迈·罗氏有限公司 用于心房纤颤的评价中的循环bmp10 (骨形态发生蛋白10)
JP7440042B2 (ja) * 2018-10-29 2024-02-28 国立大学法人 東京医科歯科大学 間質性肺炎患者の呼吸機能の低下リスクに関する情報を取得する方法及びその利用
JP7300642B2 (ja) * 2019-06-14 2023-06-30 国立大学法人浜松医科大学 特発性肺線維症の予後予測方法
CN110333358A (zh) * 2019-06-24 2019-10-15 浙江大学 一种急性肺损伤小鼠肺脏全免疫细胞特征图谱的建立方法
JP7614477B2 (ja) * 2019-08-02 2025-01-16 国立医薬品食品衛生研究所長 間質性肺炎のタンパク質診断バイオマーカー
EP4117659A4 (en) * 2020-03-13 2024-04-03 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone
CN115702351B (zh) * 2020-04-17 2026-03-31 国立医药品食品卫生研究所长 重症药疹的蛋白质诊断生物标记物
US20250122293A1 (en) * 2021-09-07 2025-04-17 Fnct Biotech, Inc. Csf3r as biomarker and therapeutic target for pulmonary fibrosis
WO2023081299A1 (en) * 2021-11-05 2023-05-11 Spiritus Therapeutics, Inc. A purified enriched population exosomes derived from individuals with a chronic progressive lung disease for noninvasive detection, staging, and medical monitoring of disease progression
CN114563562A (zh) * 2022-03-01 2022-05-31 复旦大学附属中山医院 Prdx6联合铁离子检测在ards进程监测中的应用
KR102907646B1 (ko) * 2022-08-19 2026-01-05 울산대학교 산학협력단 특발성 폐섬유증 환자의 진단 및 경과예측용 호기 바이오마커
CN119947728A (zh) * 2022-09-28 2025-05-06 勃林格殷格翰国际有限公司 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途
WO2026069490A1 (ja) * 2024-09-25 2026-04-02 国立大学法人大阪大学 進行性肺線維症診断用バイオマーカー、該バイオマーカーを用いた進行性肺線維症の検査方法及びそれらの利用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1190001A (zh) * 1996-11-18 1998-08-12 布里斯托尔-迈尔斯斯奎布公司 使用渗透促进剂促进药物渗透皮肤的方法和组合物
CN1691963A (zh) * 2002-07-19 2005-11-02 艾博特生物技术有限公司 TNFα相关疾病的治疗
US20120035067A1 (en) * 2008-09-05 2012-02-09 Naftali Kaminski Marker Panels For Idiopathic Pulmonary Fibrosis Diagnosis And Evaluation
CN102448984A (zh) * 2009-03-27 2012-05-09 酶遗传学股份有限公司 使用包含抗体-受体组合的多特异性结合蛋白的组合物和方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
JP4406206B2 (ja) * 2001-04-24 2010-01-27 バイエル コーポレーション ヒトｔｉｍｐ−１抗体
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
JP2003238592A (ja) * 2001-12-13 2003-08-27 Japan Tobacco Inc 組織及び血管の再生のための医薬及びその方法
US7888485B2 (en) * 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
EP1626279B1 (en) * 2004-08-12 2008-04-16 Roche Diagnostics GmbH Method for diagnosing liver fibrosis
CN101160528A (zh) * 2005-02-14 2008-04-09 惠氏公司 Il17-f在诊断和治疗气道炎症中的用途
EP1757940A1 (en) * 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
US20110129845A1 (en) * 2007-01-29 2011-06-02 Crc For Asthma And Airways Ltd. Method of diagnosis
WO2009028158A1 (en) * 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
US8568996B2 (en) * 2008-10-21 2013-10-29 University of Pittsburgh—of the Commonwealth System of Higher Education MMP activation peptide detection in biological samples
WO2010083392A2 (en) * 2009-01-16 2010-07-22 The Ohio State University Research Foundation Ets-2 biomarkers for fibrotic diseases and uses thereof
EP2403880A1 (en) * 2009-03-05 2012-01-11 Tripath Imaging, Inc. Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
AU2010283997B2 (en) * 2009-08-21 2015-04-09 Gilead Biologics, Inc. Methods and compositions for treatment of pulmonary fibrotic disorders
EP2496944A2 (en) * 2009-11-05 2012-09-12 Novartis AG Biomarkers predictive of progression of fibrosis
WO2011091270A2 (en) * 2010-01-21 2011-07-28 The Regents Of The University Of Michigan Biomarkers for lung disease monitoring
AU2012312515A1 (en) * 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
RU2015144149A (ru) 2013-03-15 2017-04-21 Интермьюн, Инк. Протеомные маркеры илф

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1190001A (zh) * 1996-11-18 1998-08-12 布里斯托尔-迈尔斯斯奎布公司 使用渗透促进剂促进药物渗透皮肤的方法和组合物
CN1691963A (zh) * 2002-07-19 2005-11-02 艾博特生物技术有限公司 TNFα相关疾病的治疗
US20120035067A1 (en) * 2008-09-05 2012-02-09 Naftali Kaminski Marker Panels For Idiopathic Pulmonary Fibrosis Diagnosis And Evaluation
CN102448984A (zh) * 2009-03-27 2012-05-09 酶遗传学股份有限公司 使用包含抗体-受体组合的多特异性结合蛋白的组合物和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GARY CHAN ET AL.: "Transcriptome Analysis Reveals Human Cytomegalovirus Reprograms Monocyte Differentiation toward an M1 Macrophage", 《THE JOURNAL OF IMMUNOLOGY》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107677835A (zh) * 2017-09-26 2018-02-09 上海市肺科医院 一种ae‑ipf的蛋白标记物及其应用
CN107677835B (zh) * 2017-09-26 2019-08-09 上海市肺科医院 一种ae-ipf的蛋白标记物及其应用
CN113607955A (zh) * 2020-09-16 2021-11-05 广州中医药大学顺德医院(佛山市顺德区中医院) 新型冠状病毒肺炎分期与疗效评估细胞因子标志物及其应用
CN113533750A (zh) * 2020-10-22 2021-10-22 广州中医药大学顺德医院(佛山市顺德区中医院) 一种区分新型冠状病毒肺炎患者与健康者的系统
CN117025745A (zh) * 2022-11-18 2023-11-10 中国医学科学院北京协和医院 分子标志物在诊断干燥综合征中的应用
CN117025745B (zh) * 2022-11-18 2024-02-23 中国医学科学院北京协和医院 分子标志物在诊断干燥综合征中的应用

Also Published As

Publication number Publication date
WO2014144821A1 (en) 2014-09-18
EP2972392A1 (en) 2016-01-20
US20140286929A1 (en) 2014-09-25
EP2972392A4 (en) 2017-03-22
HK1219533A1 (zh) 2017-04-07
RU2015144149A (ru) 2017-04-21
MX2015012778A (es) 2016-01-20
BR112015023699A2 (pt) 2017-07-18
JP2016519763A (ja) 2016-07-07
CA2901384A1 (en) 2014-09-18
KR20150130408A (ko) 2015-11-23
US9726677B2 (en) 2017-08-08

Similar Documents

Publication Publication Date Title
CN105122068A (zh) 蛋白质组学ipf标志物
US9200322B2 (en) Biomarkers for acute ischemic stroke
US12372530B2 (en) Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis
CN109661578B (zh) 用于区分细菌和病毒感染的蛋白质特征
US12205677B2 (en) System and method for analysis of biological data
JP2017518514A (ja) Ｌｐａ関連タンパク質及びｒｎａ発現
CN110431425B (zh) proADM作为指示不良事件的标志物
CN107003320B (zh) 慢性肾脏疾病的快速进展的生物标志物
JP7261501B2 (ja) 炎症性腸疾患の処置を改善するための腸管バリア機能の評価
JP6622722B2 (ja) 肺高血圧症バイオマーカー
RU2764766C2 (ru) Гистоны и/или proadm в качестве маркеров, свидетельствующих об органной дисфункции
CN102257387A (zh) 严重脓毒病和败血性休克期间用于快速确定死亡高风险病人的方法和试剂盒
CN108138238A (zh) 用于检测胰腺癌的组合物和方法
JP2021508046A (ja) ｐｒｏ−ＡＤＭに基づく抗生物質療法の指導
JP2018504595A (ja) 前立腺癌マーカー及びその利用
JP2012526543A5 (https=)
CN111656189A (zh) 基于合并症患者的降钙素原的抗生素疗法指导
JP2021170021A (ja) 糖尿病性腎症の早期病態の特異的な診断を可能とする検査方法
CN111065927B (zh) 作为危重患者的治疗监测标记物的pro-adm
KR102515934B1 (ko) 비감염성 폐질환 진단을 위한 바이오마커로서 cd20의 용도
JP7614477B2 (ja) 間質性肺炎のタンパク質診断バイオマーカー
CN117529664A (zh) 用于预测脓毒症和脓毒性休克的方法
JP2023528069A (ja) コロナウイルス感染症罹患対象の重症度又は合併症のマーカーとしての可溶性ｔｒｅｍ－１
Shi et al. Dickkopf-related protein 2 impairs neurovascular Wnt signalling and worsens stroke outcome
HK40017069B (en) Proadm as marker indicating an adverse event

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151202

WD01 Invention patent application deemed withdrawn after publication